Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.70
−$0.02 · -0.42%
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Previous close
$4.70
−$0.02 · -0.42%
After-hours
$4.63
−$0.07 · -1.49%
Oct 7, 5:39 PM ET
Regular session · ET · Market data may be delayed.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Day range
Current $4.70
52-week range
Current $4.70
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
58
Mixed
Risk
74
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Day range
Current $4.70
52-week range
Current $4.70
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.8M USD | 3.6M USD | 3.31M USD | 2.67M USD | 1.56M USD |
| Selling, general, and administrative | 6.49M USD | 5.93M USD | 6.07M USD | 6.58M USD | 4.5M USD |
| Operating expenses | 16.29M USD | 9.53M USD | 9.38M USD | 9.26M USD | 6.06M USD |
| Interest income | 482.08K USD | 558.49K USD | 694.61K USD | 95.75K USD | — |
| Interest expense | — | — | — | 714.08K USD | 1.09M USD |
| Depreciation and amortization | 100K USD | 100K USD | 103.71K USD | 104.04K USD | 104.04K USD |
| Operating income | −16.29M USD | −9.53M USD | −9.38M USD | −9.26M USD | −6.06M USD |
| Net income | −15.8M USD | −8.96M USD | −8.69M USD | −9.38M USD | −21.46M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
325.53% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 18, 2023 | 1:12 | — | — |
Stock split | Aug 1, 2022 | 2:25 | — | — |
Stock split | Sep 24, 2021 | 1:4 | — | — |
Stock split | Oct 23, 2019 | 1:5 | — | — |
Effective Jul 18, 2023
1:12
Effective Aug 1, 2022
2:25
Effective Sep 24, 2021
1:4
Effective Oct 23, 2019
1:5
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
